| Target Price | $56.10 |
| Price | $17.61 |
| Potential |
218.57%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Legend Biotech Corp - ADR 2027 .
The average Legend Biotech Corp - ADR target price is $56.10.
This is
218.57%
register free of charge
$81.90
365.08%
register free of charge
$24.24
37.65%
register free of charge
|
|
| A rating was issued by 23 analysts: 17 Analysts recommend Legend Biotech Corp - ADR to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Legend Biotech Corp - ADR stock has an average upside potential 2027 of
218.57%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.03 | 1.46 |
| 64.04% | 41.90% | |
| EBITDA Margin | -10.46% | 0.38% |
| 76.72% | 103.63% |
20 Analysts have issued a sales forecast Legend Biotech Corp - ADR 2026 . The average Legend Biotech Corp - ADR sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Legend Biotech Corp - ADR EBITDA forecast 2026. The average Legend Biotech Corp - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.81 | -0.01 |
| 68.75% | 98.77% | |
| P/E | negative | |
| EV/Sales | 1.86 |
20 Analysts have issued a Legend Biotech Corp - ADR forecast for earnings per share. The average Legend Biotech Corp - ADR EPS is
This results in the following potential growth metrics and future valuations:
Legend Biotech Corp - ADR...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Sep 11 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 04 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 11 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 04 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Aug 12 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


